<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02023411</url>
  </required_header>
  <id_info>
    <org_study_id>ABAR-1072013</org_study_id>
    <nct_id>NCT02023411</nct_id>
  </id_info>
  <brief_title>Efficacy of Teriparatide in Diabetic Inactive Charcot Neuroarthropathy of Foot</brief_title>
  <official_title>To Study the Efficacy of Teriparatide in Improving Remodeling of Foot Bones in Chronic Charcot Neuroarthropathy in Patients With Diabetes Mellitus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Postgraduate Institute of Medical Education and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Postgraduate Institute of Medical Education and Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic foot represents a major medical , social and economic problem worldwide.&#xD;
&#xD;
      Charcot's neuroarthropathy, being a common cause of diabetic foot, has been an intriguing&#xD;
      topic of research for endocrinologists, podiatrists and surgeons. After its first description&#xD;
      by JEAN-MARTIN CHARCOT in 1868, many theories have been put forward regarding its&#xD;
      pathophysiology , but not much research has been done for its prevention and treatment ,&#xD;
      specially the inactive stage.&#xD;
&#xD;
      The course of Charcot 's neuroarthropathy is triphasic , with the diagnosis being usually&#xD;
      missed in the active stage, henceforth the patients often come to us with a deformed foot. As&#xD;
      a consequence , the osteoclastic activity in active stage renders the foot bones&#xD;
      demineralized and weak, thus being susceptible to fracture and fragmentation.&#xD;
&#xD;
      Teriparatide is recombinant human (1-34) parathyroid molecule that has been approved for&#xD;
      post-menopausal osteoporosis and in men with primary or secondary osteoporosis. It acts by&#xD;
      preferentially stimulating osteoblast over osteoclast activity resulting in new bone&#xD;
      formation and an increase in the rate of bone remodeling which manifest as an increase in&#xD;
      skeletal mass and bone mineral density .&#xD;
&#xD;
      Keeping the pathophysiology of Charcot's foot in mind, teriparatide may be used as potential&#xD;
      treatment for inactive Charcot's neuroarthropathy but there are no studies or randomized&#xD;
      trials in this setting, till date. We hypothesize that teriparatide may increase the&#xD;
      remodeling of foot bones in Charcot's neuroarthropathy, improve bone mineral density,&#xD;
      subsequently leading to a reduction in the risk of fractures and progression of deformities.&#xD;
      This study plans to compare the effects of teriparatide in diabetes patients with inactive&#xD;
      Charcot's foot in a placebo controlled design.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Charcot neuroarthropathy (CN) was first described by Jean-Martin Charcot in a patient with&#xD;
      tabes dorsalis who recognized that peripheral neuropathy could lead to neuropathic joints.&#xD;
      This condition has many names, including Charcot osteoarthropathy, neuropathic osteo-&#xD;
      arthropathy, and many others. Charcot foot may occur as a complication of neurosyphilis,&#xD;
      syringomyelia, leprosy, poliomyelitis, congenital neuropathy and diabetes mellitus , the&#xD;
      latter currently being the most common cause of CN. Since the description of CN in 1883, its&#xD;
      pathophysiology remains an enigma, and there are no strict guidelines for the treatment of&#xD;
      this disorder.&#xD;
&#xD;
      India has more people living with diabetes than any other country of the world and diabetic&#xD;
      foot is one of the common diabetic complications found in India. The prevalence of Charcot&#xD;
      foot in diabetes is not clearly known (0.1% to nearly 30%), but it is now appreciated that&#xD;
      the condition is not as infrequent as might be generally thought. CN is characterized by&#xD;
      progressive destruction of bones and joints of the foot with accompanying osteopenia. The&#xD;
      current belief is that once the disease is triggered in a susceptible individual, it is&#xD;
      mediated through a process of uncontrolled inﬂammation in the foot. This inﬂammation leads to&#xD;
      osteolysis and is indirectly responsible for the progressive fracture and dislocation that&#xD;
      characterizes its presentation.&#xD;
&#xD;
      The pathophysiologic event is cytokine- driven elevation of the receptor activator of nuclear&#xD;
      factor kappa B ligand (RANKL), which, in turn, enhances the synthesis of nuclear factor kB&#xD;
      (NF-kB). The latter promotes osteoclast maturation and osteoclastic activity, leading to&#xD;
      osteoporosis in the affected bones. In parallel , NF-kB enhances the production of&#xD;
      osteoprotegerin from osteoblasts, in order to provide an antagonist of RANKL and mitigate its&#xD;
      effects. Ultimately, the cascade of all pathophysiologic changes leads to the development of&#xD;
      the Charcot's foot and demineralization of bones.&#xD;
&#xD;
      If the condition is correctly diagnosed and the patient is appropriately immobilized, the&#xD;
      local inflammation will subside and further bony destruction including progressive loss of&#xD;
      mineral density may be prevented. But the diagnosis of CN is frequently missed in the active&#xD;
      phase in almost 25% of cases. In the inactive stage, signs of local inﬂammation progressively&#xD;
      recede, redness subsides, and the difference in skin temperature between the two feet&#xD;
      diminishes. Most of the patients coming to our diabetes clinic present in the inactive phase&#xD;
      with stable foot deformities viz rocker bottom deformity, loss of longitudinal or transverse&#xD;
      arches, bony prominence (medial convexity) and significant demineralization of bones. These&#xD;
      foot deformities result in abnormal high-pressure areas that are particularly prone to&#xD;
      ulceration; a consequence of continued weight bearing.&#xD;
&#xD;
      Recombinant human parathyroid hormone fragment (teriparatide) is an anabolic therapy , that&#xD;
      preferentially stimulates osteoblast over osteoclast activity resulting in new bone formation&#xD;
      and an increase in the rate of bone remodeling. These effects manifest as an increase in&#xD;
      skeletal mass, bone mineral density (BMD) and bone strength, subsequently leading to a&#xD;
      reduction in the risk of fractures. It has been well established that teriparatide increases&#xD;
      bone remodeling in the skeleton through histomorphometry studies and measurements of bone&#xD;
      turnover markers (BTM), and recently direct measurements of the effect of teriparatide on the&#xD;
      site-specific metabolic activity of the skeleton has been shown in patients of osteoporosis.&#xD;
&#xD;
      Radionuclide bone scan imaging using the radiopharmaceutical 99Technetium-methylene&#xD;
      diphosphonate (MDP) has a useful role in both clinical practice and research to investigate&#xD;
      metabolic bone diseases and response to treatment. In clinical practice, bone scans are&#xD;
      reported solely on a qualitative visual interpretation of images allowing for the detection&#xD;
      of discrete changes in the skeleton in areas of focal tracer uptake. An increased 99mTc-MDP&#xD;
      skeletal uptake with teriparatide is seen in patients with osteoporosis indicating an&#xD;
      increased bone formation which was supported by BTM increases. Recently, quantitative bone&#xD;
      scintigraphy with MDP is described as a more sensitive tool to study the bone-remodeling&#xD;
      process even in CN. The potential utility of quantitative bone scanning for the diagnosis and&#xD;
      more importantly for CN activity is suggested. However, translating visual assessments into&#xD;
      quantitative data with F18 PET/ SPECT CT to study the regions of interest (ROI) and assess&#xD;
      the response to teriparatide will be more specific.&#xD;
&#xD;
      The role of teriparatide in diabetes patients with CN has not been studied, till date.&#xD;
      Keeping the pathophysiology of CN in mind, the present study plans to assess the efficacy of&#xD;
      teriparatide in chronic CN by studying the change in bone remodeling as quantitated by F18&#xD;
      SPECT CT, BMD and markers of bone turnover. We will also assess the benefits of teriparatide,&#xD;
      if any, on the foot morbidity i.e incidence of fractures, progression of deformity or need&#xD;
      for amputation over the follow up period of 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SUV Max on PET/CT Scan at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>F18 PET/CT scan of foot was performed at baseline and at 12 months following intervention. Main outcome measure was Standardised Uptake value (SUV max) with intervention. A higher score on the scale suggest better outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Events</measure>
    <time_frame>12 months</time_frame>
    <description>Any of the following will be taken as a secondary end point:&#xD;
The number of participants with&#xD;
new onset fracture&#xD;
new onset/progression of deformity&#xD;
amputation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Diabetic Neuropathic Arthropathy</condition>
  <arm_group>
    <arm_group_label>teriparatide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 diabetic patients with inactive Charcot's foot who are calcium and Vit.D sufficient will receive 20 microgram of teriparatide , subcutaneous between 8-9 p.m., daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10 diabetic patients with inactive Charcot's foot who are calcium and Vit.D sufficient will receive placebo , subcutaneous between 8-9 p.m. , daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide</intervention_name>
    <description>recombinant human parathyroid hormone (1-34) subcutaneous every day at 8-9 pm</description>
    <arm_group_label>teriparatide</arm_group_label>
    <other_name>parathyroid hormone</other_name>
    <other_name>recombinant human parathyroid hormone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinical criteria:&#xD;
&#xD;
               1. No warmth or redness of foot.&#xD;
&#xD;
               2. Difference in temperature between two foot &lt; 2 degree Centigrade.&#xD;
&#xD;
               3. If deformity present , patient able to walk without aid.&#xD;
&#xD;
               4. History of resolved active Charcot's neuroarthropathy of foot.&#xD;
&#xD;
          2. Radiological criteria: Plain X-ray foot (weight bearing lateral and oblique) showing&#xD;
             at least 3 of the following features -&#xD;
&#xD;
               1. Foot deformity.&#xD;
&#xD;
               2. Joint subluxations/dislocations.&#xD;
&#xD;
               3. Smoothening /Rounding of bone fragments.&#xD;
&#xD;
               4. Subchondral sclerosis/erosions.&#xD;
&#xD;
               5. Callus formation.&#xD;
&#xD;
               6. Joint space collapse.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active inflammatory phase of Charcot's neuroarthropathy.&#xD;
&#xD;
          2. Active on inactive Charcot's neuroarthropathy.&#xD;
&#xD;
          3. Osteomyelitis of foot bones.&#xD;
&#xD;
          4. Peripheral vascular disease.&#xD;
&#xD;
          5. Osteoporosis (T score less than or equal to -2.5 at lumbar spine or hip).&#xD;
&#xD;
          6. Renal failure ( estimated Glomerular Filtration Rate &lt; 60 ml/min).&#xD;
&#xD;
          7. Previous/present bone malignancy.&#xD;
&#xD;
          8. Previous malignancy with metastases to bone.&#xD;
&#xD;
          9. Received teriparatide earlier.&#xD;
&#xD;
         10. Hyperparathyroidism.&#xD;
&#xD;
         11. Paget's disease of bone.&#xD;
&#xD;
         12. Pregnant women.&#xD;
&#xD;
         13. Received bisphosphonates in previous 18 months.&#xD;
&#xD;
         14. Patients with ulcer on the involved foot.&#xD;
&#xD;
         15. Patients previously taking Pioglitazone. -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anil Bhansali, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>PGIMER, Chandigarh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Deptt of Endocrinology</name>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PGIMER</name>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 23, 2013</study_first_submitted>
  <study_first_submitted_qc>December 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2013</study_first_posted>
  <results_first_submitted>July 2, 2019</results_first_submitted>
  <results_first_submitted_qc>August 25, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 16, 2020</results_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Postgraduate Institute of Medical Education and Research</investigator_affiliation>
    <investigator_full_name>Ashu Rastogi</investigator_full_name>
    <investigator_title>Asst Professor , Department of Endocrinology, Post graduate institute of medical education and research</investigator_title>
  </responsible_party>
  <keyword>Teriparatide</keyword>
  <keyword>Inactive Charcot's neuroarthropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Arthropathy, Neurogenic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teriparatide</mesh_term>
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Parathyroid Hormone</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 1, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT02023411/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment performed from January 2016 and closed on December 2017</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Teriparatide</title>
          <description>Intervention Arm</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Normal saline will be subcutaneously administered at 8 pm daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Each Participant Foot was considered as one unit. Only one foot of each participant was included.</population>
      <group_list>
        <group group_id="B1">
          <title>Intervention Arm</title>
          <description>Teriparatide 20 microgram administered Subcutanoeous daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Normal saline administered Subcutanoeous daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.3" spread="8.8"/>
                    <measurement group_id="B2" value="55" spread="7.8"/>
                    <measurement group_id="B3" value="53.1" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>India</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SUVmax of affected foot</title>
          <description>F18 PETCT of affected foot was performed at baseline and SUV max ta the affected area of the foot was recorded</description>
          <units>g/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.6" lower_limit="20.8" upper_limit="45.1"/>
                    <measurement group_id="B2" value="27.2" lower_limit="15.3" upper_limit="38.5"/>
                    <measurement group_id="B3" value="27.4" lower_limit="18.1" upper_limit="41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>SUV Max on PET/CT Scan at 12 Months</title>
        <description>F18 PET/CT scan of foot was performed at baseline and at 12 months following intervention. Main outcome measure was Standardised Uptake value (SUV max) with intervention. A higher score on the scale suggest better outcome</description>
        <time_frame>12 months</time_frame>
        <population>intervention versus placebo</population>
        <group_list>
          <group group_id="O1">
            <title>Teriparatide</title>
            <description>Intervention arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>SUV Max on PET/CT Scan at 12 Months</title>
          <description>F18 PET/CT scan of foot was performed at baseline and at 12 months following intervention. Main outcome measure was Standardised Uptake value (SUV max) with intervention. A higher score on the scale suggest better outcome</description>
          <population>intervention versus placebo</population>
          <units>g/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1" spread="11.4"/>
                    <measurement group_id="O2" value="22.9" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Events</title>
        <description>Any of the following will be taken as a secondary end point:&#xD;
The number of participants with&#xD;
new onset fracture&#xD;
new onset/progression of deformity&#xD;
amputation</description>
        <time_frame>12 months</time_frame>
        <population>Participants receiving TEriparatide were observed for secondary outcomes of fractures, deformities and amputation</population>
        <group_list>
          <group group_id="O1">
            <title>Teriparatide</title>
            <description>Intervention arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo normal saline was given</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Events</title>
          <description>Any of the following will be taken as a secondary end point:&#xD;
The number of participants with&#xD;
new onset fracture&#xD;
new onset/progression of deformity&#xD;
amputation</description>
          <population>Participants receiving TEriparatide were observed for secondary outcomes of fractures, deformities and amputation</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <desc>Intervention is not known to be associated with mortality</desc>
      <group_list>
        <group group_id="E1">
          <title>Teriparatide</title>
          <description>10 diabetic patients with inactive Charcot's foot who are calcium and Vit.D sufficient will receive 20 microgram of teriparatide , subcutaneously between 8-9 p.m., daily.&#xD;
Teriparatide: recombinant human parathyroid hormone (1-34) subcutaneously every day at 8-9 pm</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>10 diabetic patients with inactive Charcot's foot who are calcium and Vit.D sufficient will receive placebo , subcutaneously between 8-9 p.m. , daily.&#xD;
Placebo: Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size Shorter follow-up duration of 12 months. Arbitrary value for SUVmax of ≥2.5 as a significant value No Histomorphometric analysis</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Ashu Rastogi</name_or_title>
      <organization>PGIMER</organization>
      <phone>9781001046</phone>
      <email>ashuendo@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

